The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 30, No. 5, pp. 527-533.
© 1996 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, T.
Right arrow Articles by Mareth, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, T.
Right arrow Articles by Mareth, T.

Research Articles

Pathophysiology and management of the serotonin syndrome

TM Brown, BP Skop, and TR Mareth

OBJECTIVE: To review the symptoms, pathophysiology, and treatment of the serotonin syndrome (SS). DATA SOURCES: A MEDLINE search (1957-1995) of the English-language literature pertaining to the SS was performed. Additional literature was obtained from reference lists of pertinent articles identified through the search. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for possible inclusion in the review. Pertinent information, as judged by the authors, was selected for discussion. DATA SYNTHESIS: The SS, an occasionally fatal disorder, is characterized by symptoms such as mental status changes, seizures, myoclonus, and blood dyscrasias. Both the central and peripheral serotonergic systems and several serotonin receptor types are involved in the symptomatology of the SS. The pathogenesis of SS may be due to endogenous as well as iatrogenic deficits in peripheral serotonin metabolism, a stimulus for release of serotonin, and interactions with other neurotransmitter systems. Lorazepam, serotonin-blockers, and nitroglycerin have been used successfully to treat SS. CONCLUSIONS: The SS is increasingly recognized and reported in the literature. Clinical and basic science research have increased our understanding of the pathophysiology, conditions, and agents that may predispose to the development of the syndrome. Newer treatment strategies are discussed.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
L. Bergeron, M. Boule, and S. Perreault
Serotonin Toxicity Associated with Concomitant Use of Linezolid
Ann. Pharmacother., May 1, 2005; 39(5): 956 - 961.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. I Velez, G. Shepherd, B. A Roth, and F. L Benitez
Serotonin Syndrome with Elevated Paroxetine Concentrations
Ann. Pharmacother., February 1, 2004; 38(2): 269 - 272.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J.-J. Pan and W. W Shen
Serotonin Syndrome Induced by Low-Dose Venlafaxine
Ann. Pharmacother., February 1, 2003; 37(2): 209 - 211.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
I. Litvan
Therapy and management of frontal lobe dementia patients
Neurology, June 12, 2001; 56(90004): S41 - 45.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
M. S. Lantz, E. Buchalter, and V. Giambanco
St. John's Wort and Antidepressant Drug Interactions in the Elderly
J Geriatr Psychiatry Neurol, April 1, 1999; 12(1): 7 - 10.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P. J GOADSBY
A triptan too far?
J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 143 - 147.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1996 by Harvey Whitney Books Company.